{"id":82429,"date":"2026-05-06T12:28:02","date_gmt":"2026-05-06T06:58:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=82429"},"modified":"2026-05-06T12:28:04","modified_gmt":"2026-05-06T06:58:04","slug":"ajanta-pharma-q4-results-fy26-pat-rs-267-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/","title":{"rendered":"Ajanta Pharma Q4 Results FY26: PAT Rs 267 Crore Up 18 Percent, FY26 Annual PAT Rs 1056 Crore"},"content":{"rendered":"<div class=\"meta-block\">\u00a0<\/div>\n<p>Ajanta Pharma Q4 results FY26 reported consolidated net profit of Rs 266.70 crore for the quarter ended March 31, 2026, up 18.4 percent year on year. The Ajanta Pharma Q4 results revenue from operations stood at Rs 1,421.64 crore, driven by strong branded generics performance in India, Africa, and Asia markets. The Ajanta Pharma Q4 results capped a fiscal year where the company&#8217;s scale, geographic diversification, and branded portfolio strategy delivered consistent earnings growth.<\/p>\n<p>The Ajanta Pharma Q4 results full-year FY26 PAT was Rs 1,056 crore, a significant milestone for the mid-cap pharma company. Ajanta Pharma Q4 results management highlighted continued momentum in the chronic therapy segment including cardiac, diabetology, and ophthalmology, which form the core of the company&#8217;s India branded business. Africa exports also contributed strongly to Ajanta Pharma Q4 results revenue, with the region showing resilience despite logistical challenges arising from the Iran-UAE conflict in the Gulf transit corridor.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Ajanta_Pharma_Q4_FY26_Results_at_a_Glance\" title=\"Ajanta Pharma Q4 FY26 Results at a Glance\">Ajanta Pharma Q4 FY26 Results at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Key_Highlights_from_Ajanta_Pharma_Q4_results\" title=\"Key Highlights from Ajanta Pharma Q4 results\">Key Highlights from Ajanta Pharma Q4 results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#18_Percent_PAT_Growth_Reflects_Quality_Branded_Mix_in_Ajanta_Pharma_Q4_Results\" title=\"18 Percent PAT Growth Reflects Quality Branded Mix in Ajanta Pharma Q4 Results\">18 Percent PAT Growth Reflects Quality Branded Mix in Ajanta Pharma Q4 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#FY26_PAT_Crossing_Rs_1056_Crore_is_Milestone_in_Ajanta_Pharma_Q4_Results_Commentary\" title=\"FY26 PAT Crossing Rs 1056 Crore is Milestone in Ajanta Pharma Q4 Results Commentary\">FY26 PAT Crossing Rs 1056 Crore is Milestone in Ajanta Pharma Q4 Results Commentary<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#What_Drove_Ajanta_Pharma_Q4_FY26_Performance\" title=\"What Drove Ajanta Pharma Q4 FY26 Performance\">What Drove Ajanta Pharma Q4 FY26 Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Outlook_for_FY27\" title=\"Outlook for FY27\">Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#What_was_the_Ajanta_Pharma_Q4_results_FY26_net_profit\" title=\"What was the Ajanta Pharma Q4 results FY26 net profit?\">What was the Ajanta Pharma Q4 results FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#What_was_the_Ajanta_Pharma_Q4_results_FY26_revenue\" title=\"What was the Ajanta Pharma Q4 results FY26 revenue?\">What was the Ajanta Pharma Q4 results FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#What_are_the_key_strengths_in_Ajanta_Pharma_Q4_results_FY26\" title=\"What are the key strengths in Ajanta Pharma Q4 results FY26?\">What are the key strengths in Ajanta Pharma Q4 results FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#What_is_the_outlook_after_Ajanta_Pharma_Q4_results_FY26\" title=\"What is the outlook after Ajanta Pharma Q4 results FY26?\">What is the outlook after Ajanta Pharma Q4 results FY26?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-fy26-pat-rs-267-crore\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q4_FY26_Results_at_a_Glance\"><\/span><strong>Ajanta Pharma Q4 FY26 Results at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Change \/ Context<\/th>\n<\/tr>\n<tr>\n<td>Q4 Consolidated PAT<\/td>\n<td>Rs 266.70 crore<\/td>\n<td>+18.4% YoY<\/td>\n<\/tr>\n<tr>\n<td>Q4 Revenue from Operations<\/td>\n<td>Rs 1,421.64 crore<\/td>\n<td>Across India and Africa<\/td>\n<\/tr>\n<tr>\n<td>FY26 Full Year PAT<\/td>\n<td>Rs 1,056 crore<\/td>\n<td>Milestone for mid-cap pharma<\/td>\n<\/tr>\n<tr>\n<td>India Branded Business<\/td>\n<td>Growing double digits<\/td>\n<td>Cardiac, diabetology, ophthal<\/td>\n<\/tr>\n<tr>\n<td>Africa Exports<\/td>\n<td>Resilient despite headwinds<\/td>\n<td>Key geography for Ajanta<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margins<\/td>\n<td>Above 25%<\/td>\n<td>Maintained on branded mix<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Track live Ajanta Pharma financials, analyst ratings and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Highlights_from_Ajanta_Pharma_Q4_results\"><\/span><strong>Key Highlights from Ajanta Pharma Q4 results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"18_Percent_PAT_Growth_Reflects_Quality_Branded_Mix_in_Ajanta_Pharma_Q4_Results\"><\/span><strong>18 Percent PAT Growth Reflects Quality Branded Mix in Ajanta Pharma Q4 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma Q4 results PAT of Rs 266.70 crore, up 18.4 percent, was driven by branded generics operating leverage in India and high-margin therapeutic areas. Chronic therapies including cardiac and diabetology command superior margins versus acute therapies. The Ajanta Pharma Q4 results EBITDA margins remained above 25 percent, reflecting pricing power in the branded segment. R&amp;D spend as a percentage of revenue remained steady at approximately 6 to 7 percent, protecting the innovation pipeline that underpins Ajanta Pharma Q4 results long-term competitiveness.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY26_PAT_Crossing_Rs_1056_Crore_is_Milestone_in_Ajanta_Pharma_Q4_Results_Commentary\"><\/span><strong>FY26 PAT Crossing Rs 1056 Crore is Milestone in Ajanta Pharma Q4 Results Commentary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma Q4 results management confirmed full-year FY26 PAT of Rs 1,056 crore, crossing the Rs 1,000 crore threshold for the first time. This milestone reflects the successful execution of the company&#8217;s branded generics strategy across India, Africa, and South-East Asia markets embedded in Ajanta Pharma Q4 results. The FY26 performance provides a strong base for FY27 earnings growth as new product launches in the ophthalmology and dermatology segments are planned.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Drove_Ajanta_Pharma_Q4_FY26_Performance\"><\/span><strong>What Drove Ajanta Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma Q4 results performance was driven by strong India branded generic volumes in chronic segments, Africa institutional business resilience, and contained input cost inflation. The ophthalmic and cardiac therapy franchises delivered above-market growth in Ajanta Pharma Q4 results. Operating leverage from fixed manufacturing costs at Palghar and Dahej facilities improved EBITDA margins. The company&#8217;s differentiated branded strategy in emerging markets gives Ajanta Pharma Q4 results a premium earnings quality versus generic-focused peers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Outlook_for_FY27\"><\/span><strong>Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Ajanta Pharma Q4 results, FY27 outlook is positive with new chronic therapy launches in India, Africa institutional contract wins, and potential US generics business contribution from FDA-cleared products. Management at Ajanta Pharma Q4 results briefing highlighted R&amp;D pipeline progress in complex generics and biosimilars that could provide incremental revenue beyond FY27. Analyst targets for Ajanta Pharma post Q4 results range between Rs 2,800 and Rs 3,400.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma Q4 results FY26 confirm 18.4 percent PAT growth to Rs 266.70 crore and FY26 full-year PAT of Rs 1,056 crore, a historic milestone. Revenue of Rs 1,421.64 crore on strong branded generics performance in India and Africa positions Ajanta Pharma Q4 results as a quality mid-cap pharma compounder. Track Ajanta Pharma Q4 results live data on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live Ajanta Pharma Q4 results tracking and expert research.<\/p>\n<p><em>Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Ajanta_Pharma_Q4_results_FY26_net_profit\"><\/span><strong>What was the Ajanta Pharma Q4 results FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma Q4 results FY26 reported consolidated PAT of Rs 266.70 crore, up 18.4 percent year on year. FY26 full-year PAT crossed Rs 1,056 crore, the first time above Rs 1,000 crore in company history.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Ajanta_Pharma_Q4_results_FY26_revenue\"><\/span><strong>What was the Ajanta Pharma Q4 results FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma Q4 results FY26 revenue from operations was Rs 1,421.64 crore, driven by branded generics in India chronic therapy segments and Africa institutional business exports.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_strengths_in_Ajanta_Pharma_Q4_results_FY26\"><\/span><strong>What are the key strengths in Ajanta Pharma Q4 results FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key strengths in Ajanta Pharma Q4 results include branded generics pricing power in India, Africa market diversification, EBITDA margins above 25 percent, and a growing chronic therapy franchise in cardiac, diabetology, and ophthalmology.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_after_Ajanta_Pharma_Q4_results_FY26\"><\/span><strong>What is the outlook after Ajanta Pharma Q4 results FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following Ajanta Pharma Q4 results, FY27 outlook is positive with new chronic launches, Africa contract wins, and US generics pipeline. Analyst targets range Rs 2,800 to Rs 3,400 for Ajanta Pharma post Q4 results.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma Q4 results FY26: PAT Rs 266.70 crore up 18.4%, revenue Rs 1,421.64 crore. FY26 full-year PAT Rs 1,056 crore. Strong branded generics and Africa exports drive growth.<\/p>\n","protected":false},"author":26,"featured_media":82441,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-82429","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778050707:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Ajanta Pharma Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Ajanta Pharma Q4 Results FY26 PAT Rs 267 Crore Up 18 Percent Revenue Rs 1422 Crore FY26 PAT Rs 1056 Crore"],"rank_math_description":["Ajanta Pharma Q4 results FY26: PAT Rs 266.70 crore up 18.4%, revenue Rs 1,421.64 crore. FY26 full-year PAT Rs 1,056 crore. Strong branded generics and Africa exports drive growth."],"_thumbnail_id":["82441"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10409"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/06122724\/Ajanta-Pharma-Q4-Results-FY26.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=82429"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82429\/revisions"}],"predecessor-version":[{"id":82444,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82429\/revisions\/82444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/82441"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=82429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=82429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=82429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}